Trump says envoy Witkoff had productive meeting with Putin
LONDON - Cambridge Cognition Holdings (LON:COGC) PLC (AIM: COG), a developer of digital brain health assessment tools, has announced the expansion of its services with the introduction of an in-house Rater Training program. This addition is aimed at enhancing the reliability of Central Nervous System (CNS) clinical study data collected by trial staff.
The service is expected to complement the Group’s existing electronic Clinical Outcome Assessments (eCOA) and Automated Quality Assurance tools, positioning Cambridge Cognition as a single platform provider in the CNS clinical trials market. This market, which includes rater training services, generated $5.2 billion in revenue in 2023, with over half of this coming from the services segment. Forecasts suggest a growth rate of 27% annually through 2030.
Barbara Enger RN MSN, with two decades of experience in eCOA service delivery and acting as a consultant for Cambridge Cognition, emphasized the importance of rater training in ensuring the collection of dependable data in CNS studies. She highlighted that raters must not only possess comprehensive knowledge of endpoint instruments but also maintain consistent reliability in their administration throughout the study's duration.
Rob Baker, Joint Managing Director and Chief Operating Officer of Cambridge Cognition, expressed confidence that the new Rater Training service will facilitate market expansion for the company’s brain health software tools. He noted the service's potential to enhance the accuracy, efficiency, and reliability that pharmaceutical companies require in CNS clinical trials. The company has already secured initial Rater Training contracts and anticipates introducing the service to new and existing customers shortly.
The information in this article is based on a press release statement from Cambridge Cognition Holdings PLC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.